Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
In his talk titled Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy, Dr. Machlenkin will discuss Compugen's discovery ...
The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and ...
... cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapyMultikine* (Leukocyte Interleukin, Injection).
"There is a clinical need for a better test for the up to 80 percent of patients withbladder cancer whose cancer recurs, since many of the currently ... (I have found the molecular biomarker test CxBladder a good way of monitoring)
Patna: Arsenic is known to be one of the causative factors of gall bladder cancer in Bihar. However, a recent research by city's Mahavir Cancer ...
The FDA granted the first Breakthrough Therapy Designation for MPDL3280A in metastatic bladder cancer in 2014. Ongoing pivotal studies of ...
Roche's MPDL3280A granted FDA Breakthrough Therapy Designation in non-small cell lung cancer - The Pharma Letter
The recently released immune response data from the Phase 1 trial of HS-410 in bladder cancer is exciting and supports the mechanism of Heat's ...
Roche, meanwhile, added boasting rights for a second BTD on its PD-L1 drug, which had earlier won a nod for bladder cancer. The pharma giant has ...
Cancer of the pancreas – an organ that lies behind the lower part of your stomach - accounts for only two percent of cancers diagnosed in the U.S. ...
It seems like the incidence of pancreatic cancer is on the rise, but it may just be that advances in radiology and CT scans are helping with improved ...
There are today at least 325 targeted molecular therapies known to affect more than 252 specific intracellular signaling pathways for the treatment of ...
Only around 6% of people with pancreatic cancer survive more than 5 years after diagnosis. The main reason is because of the lack of reliable tools to ...
Science Daily Cancer News
Analysis of key breast cancer genes reveals distinct profiles for African-American, European-American women
Epidemiologists have determined that gene variations associated with breast cancer risk diverged significantly between African-American and women of European descent, a large study shows.
"Increasingly physicians are being presented with health economic analyses in mainstream medical journals as a means of potentially influencing their prescribing. However, it is only when you understand the multiple assumptions behind these calculations that you can see that they are by no means absolute truths," says one expert.
Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will live five years after their diagnosis. One reason for this high mortality rate is the lack of effective tools to detect pancreatic cancer early enough to allow its surgical removal. Now researchers are now one step closer to devising an approach to detect pancreatic cancer earlier.
In the search for new approaches to treat ERBB2 positive breast cancers that have become drug-resistant, researchers have discovered a novel cancer resistance mechanism. "Approximately 25% of breast cancers overexpress and depend on the protein ERBB2 for survival," said the lead investigator. "Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventually they become ineffective as the cancer develops resistance to those drugs."
New research may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery, scientists report.
Epigenetic 'signatures' have been identified that could help clinicians tell the difference between highly aggressive and more benign forms of triple-negative breast cancer. The study reveals "distinct methylation patterns" in the primary biopsy breast cancer cells indicating better or worse prognosis.
Among nonsmokers who had diabetes, those who took the diabetes drug metformin had a decrease in lung cancer risk, scientists report. Metformin use for five or more years was associated with a 31 percent decrease in the risk for adenocarcinoma, the most common type of lung cancer diagnosed in nonsmokers, and an 82 percent increase in the risk for small-cell carcinoma, a type of lung cancer often diagnosed in smokers, they say.
Cancer researchers must use one of the world's fastest computers to detect which versions of genes are only found in cancer cells. Every form of cancer, even every tumor, has its own distinct variants, they report.
Commonly used anticancer drugs may help to make tumor cells dormant, scientists report. "Our results explain why some tumor cells scattered through the body are committed to remaining harmless for years, while others cause active disease," said one investigator. "In finding this master switch we found a way to analyze tumor cells before treatment to determine the risk of a cancer recurrence or metastasis."
Tambahkan Komentar